Nanologica AB (publ)
SSE:NICA.ST
7.18 (SEK) • At close February 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.443 | 1.555 | 12.914 | 16.135 | 10.227 | 4.145 | 2.6 | 2 | 3.263 | 1.645 | 4.739 | 3.564 |
| Cost of Revenue
| 49.349 | -1.68 | 7.994 | 1.142 | 1.562 | 2.619 | -3.868 | 0.008 | -3.153 | -3.889 | 2.164 | 1.621 |
| Gross Profit
| -47.906 | 3.235 | 4.92 | 14.993 | 8.665 | 1.526 | 6.467 | 1.992 | 6.416 | 5.535 | 2.576 | 1.943 |
| Gross Profit Ratio
| -33.199 | 2.08 | 0.381 | 0.929 | 0.847 | 0.368 | 2.488 | 0.996 | 1.966 | 3.364 | 0.543 | 0.545 |
| Reseach & Development Expenses
| 7.301 | 4.139 | 3.819 | 2.635 | 2.496 | 2.651 | 2.585 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 14.142 | 12.583 | 11.511 | 10.745 | 8.236 | 11.231 | 10.53 | 8.132 | 8.522 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 40.504 | 14.142 | 12.583 | 11.511 | 10.745 | 8.236 | 11.231 | 10.53 | 8.132 | 8.522 | 13.744 | 7.922 |
| Other Expenses
| -9.785 | 39.23 | 31.368 | 23.587 | 17.529 | 14.587 | 0 | 1.543 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 17.086 | 53.372 | 43.951 | 35.098 | 28.274 | 22.823 | 25.762 | 24.015 | 20.426 | 20.02 | 12.647 | 7.004 |
| Operating Income
| -64.992 | -50.137 | -39.031 | -20.105 | -19.609 | -21.32 | -19.302 | -22.198 | -14.143 | -14.73 | -10.131 | -4.838 |
| Operating Income Ratio
| -45.04 | -32.242 | -3.022 | -1.246 | -1.917 | -5.143 | -7.424 | -11.097 | -4.335 | -8.953 | -2.138 | -1.358 |
| Total Other Income Expenses Net
| -10.165 | -5.094 | -5.798 | -2.094 | 0.021 | 0.431 | -0.793 | -0.262 | -0.148 | 0.006 | 0.067 | -0.197 |
| Income Before Tax
| -75.157 | -55.231 | -44.829 | -22.199 | -19.588 | -20.889 | -20.095 | -22.46 | -14.291 | -14.724 | -10.064 | -5.036 |
| Income Before Tax Ratio
| -52.084 | -35.518 | -3.471 | -1.376 | -1.915 | -5.039 | -7.729 | -11.228 | -4.38 | -8.949 | -2.124 | -1.413 |
| Income Tax Expense
| 0 | -0.141 | 5.303 | 2.627 | 1.885 | 1.649 | 0.108 | 0.592 | 0.101 | 0.391 | 0 | 0 |
| Net Income
| -75.157 | -55.09 | -50.132 | -24.826 | -21.473 | -20.889 | -20.095 | -22.46 | -14.291 | -14.724 | -10.064 | -5.036 |
| Net Income Ratio
| -52.084 | -35.428 | -3.882 | -1.539 | -2.1 | -5.039 | -7.729 | -11.228 | -4.38 | -8.949 | -2.124 | -1.413 |
| EPS
| -2.05 | -1.81 | -1.77 | -1.03 | -1.27 | -1.8 | -4.35 | -6.18 | -6.33 | -8.01 | -7.84 | -4.52 |
| EPS Diluted
| -2.05 | -1.81 | -1.77 | -1.03 | -1.27 | -1.8 | -4.35 | -5.95 | -6.09 | -4.3 | -7.84 | -4.52 |
| EBITDA
| -57.666 | -38.501 | -29.063 | -13.9 | -15.487 | -17.773 | -15.857 | -18.472 | -11.421 | -12.767 | -6.487 | -3.596 |
| EBITDA Ratio
| -39.963 | -24.759 | -2.251 | -0.861 | -1.514 | -4.288 | -6.099 | -9.234 | -3.501 | -7.76 | -1.369 | -1.009 |